Novira Therapeutics gets $11m first tranche of Series A for capsid-targeting antivirals
This article was originally published in Scrip
Novira Therapeutics, a small Radnor, Pennsylvania-based antiviral drug discovery firm with oral capsid-targeting medicines in development for large indications, has raised the first $11 million of a two-tranche, $23 million Series A financing round to advance small molecules for the treatment of hepatitis B virus (HBV) and HIV into the clinic.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.